Is CERo Therapeutics Holdings, Inc. (CERO) a Buy, Sell, or Hold?
OTC : CERO
CERo Therapeutics Holdings, Inc.
$0.011 USD
$0.0 (10.0%)
- Volume
- 0
- Average Volume
- 782K
- Market Capitalization
- $496.24K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.90
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.14
Company Overview
OTC
Christopher Ehrlich
Biotechnology
Healthcare
CERO
8
US
USD
Liquidity Metrics
-0.06
0.14
0.14
0.08
0.00
Sales & Valuation
-$
0.00
-0.03
-0.03
-0.50
Profitability
-$22.58
-$19.92M
0.00%
0.00%
396.51%
-938.74%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-95.22
1/9
-$9.75M
$2.21M
$11.46M
-$19.07M
Key Metrics (TTM)
$191.98K
0.00
-0.01
0.14
396.51%
211.98%
-7198.81%
-3191.06%
-2568 days
Company Executives
| Name | Title |
|---|---|
| Christopher Ehrlich | Chief Executive Officer & Chair |
| Kristen Pierce | Chief Development Officer |
| Andrew Albert Kucharchuk | Chief Financial Officer |
| Lawrence Corey | Co-founder & Head of Scientific Advisory Board |
Poll Results
No votes yet today — be the first to share your view!
About CERo Therapeutics Holdings, Inc. (OTC:CERO) Stock
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California. ...
2026-06-15 08:15:00
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies
2026-06-15 08:15:00
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN FRANCISCO, Calif, June 15, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
2026-05-11 08:15:00
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
2026-05-11 08:15:00
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing next-generation engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has completed dosing and the 28-day dose-limiting toxicity ("DLT") assessment period for all three patients in the second cohort of its Phase 1 CERTAIN-T clinical trial of CER-1236 in hematologic malignancies.
Frequently Asked Questions
-
What is the current CERo Therapeutics Holdings, Inc. (CERO) stock price?
-
CERo Therapeutics Holdings, Inc.(OTC:CERO) stock price is $0.011 in the last trading session. During the trading session, CERO stock reached the peak price of $8.9 while $0.007 was the lowest point it dropped to. The percentage change in CERO stock occurred in the recent session was 10.0% while the dollar amount for the price change in CERO stock was $0.0.
-
CERO's industry and sector of operation?
-
The OTC listed CERO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CERO?
-
Christopher Ehrlich | Chief Executive Officer & Chair
Kristen Pierce | Chief Development Officer
Andrew Albert Kucharchuk | Chief Financial Officer
Lawrence Corey | Co-founder & Head of Scientific Advisory Board
| -
How many employees does CERO have?
-
Number of CERO employees currently stands at 8. CERO operates from 201 Haskins Way, South San Francisco, CA 94080, US.
-
Link for CERO official website?
-
Official Website of CERO is: https://www.cero.bio
-
How do I contact CERO?
-
CERO could be contacted at phone #(650) 407-2376 and can also be accessed through its website. CERO operates from 201 Haskins Way, South San Francisco, CA 94080, US.
-
How many shares of CERO are traded daily?
-
The average number of CERO shares traded daily for last 3 months was 782K.
-
What is the market cap of CERO currently?
-
The market value of CERO currently stands at $496.24K with its latest stock price at $0.011